Clinical Research Directory
Browse clinical research sites, groups, and studies.
AAV Gene Therapy Study for Subjects with PKU
Sponsor: BioMarin Pharmaceutical
Summary
This is a Phase 1/2, open-label, dose escalation study to evaluate the safety, efficacy and tolerability of BMN 307 in adult PKU subjects with PAH deficiency. Participants will receive a single administration of BMN 307 and will be followed for safety and efficacy.
Official title: A Phase 1/2 Open-Label, Dose Escalation Study to Determine the Safety and Efficacy of BMN 307, an Adeno-Associated Virus Vector-Mediated Gene Transfer of Human Phenylalanine Hydroxylase in Subjects with Phenylketonuria
Key Details
Gender
All
Age Range
15 Years - Any
Study Type
INTERVENTIONAL
Enrollment
100
Start Date
2020-09-24
Completion Date
2027-12
Last Updated
2024-12-12
Healthy Volunteers
No
Conditions
Interventions
BMN 307
AAV Gene Therapy Infusion
Locations (3)
University of South Florida
Tampa, Florida, United States
Morristown Medical Center
Morristown, New Jersey, United States
University Hospital Birmingham NHS Foundation Trust
Birmingham, United Kingdom